6-((5-Cyanopyrazin-2-yl)amino)-N,N-dimethyl-4-((piperidin-4-ylmethyl)amino)nicotinamide

ID: ALA4750705

PubChem CID: 59613528

Max Phase: Preclinical

Molecular Formula: C19H24N8O

Molecular Weight: 380.46

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  CN(C)C(=O)c1cnc(Nc2cnc(C#N)cn2)cc1NCC1CCNCC1

Standard InChI:  InChI=1S/C19H24N8O/c1-27(2)19(28)15-11-25-17(26-18-12-22-14(8-20)10-24-18)7-16(15)23-9-13-3-5-21-6-4-13/h7,10-13,21H,3-6,9H2,1-2H3,(H2,23,24,25,26)

Standard InChI Key:  QPWHMDATXFXAQF-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 28 30  0  0  0  0  0  0  0  0999 V2000
    3.1572  -18.4311    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1561  -19.2585    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8709  -19.6715    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.5875  -19.2581    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5847  -18.4275    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8691  -18.0183    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3027  -19.6695    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.0166  -19.2558    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7284  -19.6677    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4418  -19.2547    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.4410  -18.4288    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7207  -18.0175    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0103  -18.4328    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.1489  -18.0124    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8622  -17.5977    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.8667  -17.1932    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.5800  -16.7785    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5775  -15.9535    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2922  -15.5429    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2916  -14.7214    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5777  -14.3071    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.8626  -14.7206    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8615  -15.5483    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4426  -18.0188    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4424  -17.1937    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.7281  -18.4314    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.0135  -18.0191    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7283  -19.2565    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  4  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13  8  1  0
 14 15  3  0
 11 14  1  0
  6 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 18 23  1  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
  1 24  1  0
 24 25  2  0
 24 26  1  0
 26 27  1  0
 26 28  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4750705

   6-[(5-cyanopyrazin-2-yl)amino]-N,N-dimethyl-4-(piperidin-4-ylmethylamino)pyridine-3-carboxamide

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 380.46

Molecular Weight (Monoisotopic): 380.2073

AlogP: 1.60

#Rotatable Bonds: 6

Polar Surface Area: 118.86

Molecular Species: BASE

HBA: 8

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 9

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 10.28

CX Basic pKa: 9.70

CX LogP: -0.02

CX LogD: -2.08

Aromatic Rings: 2

Heavy Atoms: 28

QED Weighted: 0.69

Np Likeness Score: -1.07

References

1. Osborne JD,Matthews TP,McHardy T,Proisy N,Cheung KM,Lainchbury M,Brown N,Walton MI,Eve PD,Boxall KJ,Hayes A,Henley AT,Valenti MR,De Haven Brandon AK,Box G,Jamin Y,Robinson SP,Westwood IM,van Montfort RL,Leonard PM,Lamers MB,Reader JC,Aherne GW,Raynaud FI,Eccles SA,Garrett MD,Collins I.  (2016)  Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).,  59  (11.0): [PMID:27167172] [10.1021/acs.jmedchem.5b01938]

Source

Source(1):

• Scientific Literature